Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

PEN vs ISRG vs NVCR vs SYK vs MDT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
PEN
Penumbra, Inc.

Medical - Devices

HealthcareNYSE • US
Market Cap$12.67B
5Y Perf.+86.9%
ISRG
Intuitive Surgical, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$159.85B
5Y Perf.+132.8%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$2.04B
5Y Perf.-73.5%
SYK
Stryker Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$109.33B
5Y Perf.+45.8%
MDT
Medtronic plc

Medical - Devices

HealthcareNYSE • IE
Market Cap$97.62B
5Y Perf.-22.8%

PEN vs ISRG vs NVCR vs SYK vs MDT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
PEN logoPEN
ISRG logoISRG
NVCR logoNVCR
SYK logoSYK
MDT logoMDT
IndustryMedical - DevicesMedical - Instruments & SuppliesMedical - Instruments & SuppliesMedical - DevicesMedical - Devices
Market Cap$12.67B$159.85B$2.04B$109.33B$97.62B
Revenue (TTM)$1.45B$10.58B$674M$25.12B$35.48B
Net Income (TTM)$171M$2.98B$-173M$3.25B$4.61B
Gross Margin67.4%66.3%75.2%63.5%61.9%
Operating Margin12.9%30.5%-27.2%22.4%17.9%
Forward P/E65.8x43.3x19.1x13.8x
Total Debt$220M$303M$290M$14.86B$28.52B
Cash & Equiv.$187M$3.37B$103M$4.01B$2.22B

PEN vs ISRG vs NVCR vs SYK vs MDTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

PEN
ISRG
NVCR
SYK
MDT
StockMay 20May 26Return
Penumbra, Inc. (PEN)100186.9+86.9%
Intuitive Surgical,… (ISRG)100232.8+132.8%
NovoCure Limited (NVCR)10026.5-73.5%
Stryker Corporation (SYK)100145.8+45.8%
Medtronic plc (MDT)10077.2-22.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: PEN vs ISRG vs NVCR vs SYK vs MDT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MDT leads in 3 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and dividend income and shareholder returns. Penumbra, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. ISRG also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
PEN
Penumbra, Inc.
The Growth Play

PEN is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.

  • Rev growth 17.5%, EPS growth 11.6%, 3Y rev CAGR 18.3%
  • Lower volatility, beta 0.23, Low D/E 15.4%, current ratio 6.64x
  • Beta 0.23, current ratio 6.64x
  • Beta 0.23 vs NVCR's 2.15, lower leverage
Best for: growth exposure and sleep-well-at-night
ISRG
Intuitive Surgical, Inc.
The Long-Run Compounder

ISRG ranks third and is worth considering specifically for long-term compounding.

  • 5.5% 10Y total return vs PEN's 5.0%
  • 20.5% revenue growth vs MDT's 3.6%
  • 28.2% margin vs NVCR's -25.7%
Best for: long-term compounding
NVCR
NovoCure Limited
The Healthcare Pick

NVCR lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
SYK
Stryker Corporation
The Value Pick

SYK is the clearest fit if your priority is valuation efficiency.

  • PEG 1.28 vs MDT's 35.17
Best for: valuation efficiency
MDT
Medtronic plc
The Income Pick

MDT carries the broadest edge in this set and is the clearest fit for income & stability.

  • Dividend streak 36 yrs, beta 0.42, yield 3.7%
  • Better valuation composite
  • 3.7% yield, 36-year raise streak, vs SYK's 1.2%, (3 stocks pay no dividend)
  • 175.8% ROA vs NVCR's -16.5%, ROIC 6.0% vs -16.4%
Best for: income & stability
See the full category breakdown
CategoryWinnerWhy
GrowthISRG logoISRG20.5% revenue growth vs MDT's 3.6%
ValueMDT logoMDTBetter valuation composite
Quality / MarginsISRG logoISRG28.2% margin vs NVCR's -25.7%
Stability / SafetyPEN logoPENBeta 0.23 vs NVCR's 2.15, lower leverage
DividendsMDT logoMDT3.7% yield, 36-year raise streak, vs SYK's 1.2%, (3 stocks pay no dividend)
Momentum (1Y)PEN logoPEN+11.6% vs SYK's -24.5%
Efficiency (ROA)MDT logoMDT175.8% ROA vs NVCR's -16.5%, ROIC 6.0% vs -16.4%

PEN vs ISRG vs NVCR vs SYK vs MDT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

PENPenumbra, Inc.
FY 2022
Peripheral Vascular
59.0%$499M
Neuro
41.0%$348M
ISRGIntuitive Surgical, Inc.
FY 2025
Instruments and Accessories
59.8%$6.0B
Systems
24.6%$2.5B
Services
15.6%$1.6B
NVCRNovoCure Limited

Segment breakdown not available.

SYKStryker Corporation
FY 2025
MedSurg
62.3%$15.6B
Orthopaedics
37.7%$9.5B
MDTMedtronic plc
FY 2025
Cardiac and Vascular Group
37.3%$12.5B
Neuroscience Group
29.4%$9.8B
Medical Surgical
25.1%$8.4B
Diabetes Group
8.2%$2.8B

PEN vs ISRG vs NVCR vs SYK vs MDT — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLISRGLAGGINGSYK

Income & Cash Flow (Last 12 Months)

ISRG leads this category, winning 4 of 6 comparable metrics.

MDT is the larger business by revenue, generating $35.5B annually — 52.6x NVCR's $674M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricPEN logoPENPenumbra, Inc.ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedSYK logoSYKStryker Corporati…MDT logoMDTMedtronic plc
RevenueTrailing 12 months$1.5B$10.6B$674M$25.1B$35.5B
EBITDAEarnings before interest/tax$200M$3.8B-$165M$6.3B$9.4B
Net IncomeAfter-tax profit$171M$3.0B-$173M$3.2B$4.6B
Free Cash FlowCash after capex$213M$2.8B-$48M$4.3B$5.4B
Gross MarginGross profit ÷ Revenue+67.4%+66.3%+75.2%+63.5%+61.9%
Operating MarginEBIT ÷ Revenue+12.9%+30.5%-27.2%+22.4%+17.9%
Net MarginNet income ÷ Revenue+11.8%+28.2%-25.7%+12.9%+13.0%
FCF MarginFCF ÷ Revenue+14.6%+26.8%-7.1%+17.1%+15.2%
Rev. Growth (YoY)Latest quarter vs prior year+15.6%+23.0%+12.3%+11.4%+8.8%
EPS Growth (YoY)Latest quarter vs prior year-18.0%+18.8%-100.0%+56.0%-11.9%
ISRG leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

MDT leads this category, winning 5 of 7 comparable metrics.

At 21.1x trailing earnings, MDT trades at a 70% valuation discount to PEN's 71.3x P/E. Adjusting for growth (PEG ratio), SYK offers better value at 2.29x vs MDT's 35.17x — a lower PEG means you pay less per unit of expected earnings growth.

MetricPEN logoPENPenumbra, Inc.ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedSYK logoSYKStryker Corporati…MDT logoMDTMedtronic plc
Market CapShares × price$12.7B$159.8B$2.0B$109.3B$97.6B
Enterprise ValueMkt cap + debt − cash$12.7B$156.8B$2.2B$120.2B$123.9B
Trailing P/EPrice ÷ TTM EPS71.29x57.19x-14.66x33.98x21.09x
Forward P/EPrice ÷ next-FY EPS est.65.80x43.35x19.06x13.80x
PEG RatioP/E ÷ EPS growth rate2.63x2.29x35.17x
EV / EBITDAEnterprise value multiple61.47x43.28x19.76x14.06x
Price / SalesMarket cap ÷ Revenue9.03x15.88x3.11x4.35x2.91x
Price / BookPrice ÷ Book value/share8.87x9.10x5.86x4.87x2.04x
Price / FCFMarket cap ÷ FCF72.45x64.18x25.53x18.83x
MDT leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

ISRG leads this category, winning 5 of 9 comparable metrics.

ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-51 for NVCR. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), PEN scores 7/9 vs NVCR's 5/9, reflecting strong financial health.

MetricPEN logoPENPenumbra, Inc.ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedSYK logoSYKStryker Corporati…MDT logoMDTMedtronic plc
ROE (TTM)Return on equity+12.3%+16.9%-50.8%+15.0%+9.4%
ROA (TTM)Return on assets+9.6%+14.8%-16.5%+6.9%+175.8%
ROICReturn on invested capital+11.3%+15.0%-16.4%+11.4%+6.0%
ROCEReturn on capital employed+12.5%+16.5%-28.9%+13.0%+7.5%
Piotroski ScoreFundamental quality 0–976566
Debt / EquityFinancial leverage0.15x0.02x0.85x0.66x0.59x
Net DebtTotal debt minus cash$33M-$3.1B$187M$10.8B$26.3B
Cash & Equiv.Liquid assets$187M$3.4B$103M$4.0B$2.2B
Total DebtShort + long-term debt$220M$303M$290M$14.9B$28.5B
Interest CoverageEBIT ÷ Interest expense304.65x-96.80x6.72x9.08x
ISRG leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ISRG leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ISRG five years ago would be worth $16,174 today (with dividends reinvested), compared to $983 for NVCR. Over the past 12 months, PEN leads with a +11.6% total return vs SYK's -24.5%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.1% vs NVCR's -36.4% — a key indicator of consistent wealth creation.

MetricPEN logoPENPenumbra, Inc.ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedSYK logoSYKStryker Corporati…MDT logoMDTMedtronic plc
YTD ReturnYear-to-date+4.1%-19.9%+36.4%-17.8%-20.0%
1-Year ReturnPast 12 months+11.6%-16.4%+2.6%-24.5%-5.5%
3-Year ReturnCumulative with dividends+3.7%+48.5%-74.2%+2.4%-6.3%
5-Year ReturnCumulative with dividends+22.3%+61.7%-90.2%+17.5%-29.2%
10-Year ReturnCumulative with dividends+501.4%+549.2%+38.5%+179.2%+24.3%
CAGR (3Y)Annualised 3-year return+1.2%+14.1%-36.4%+0.8%-2.1%
ISRG leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — PEN and NVCR each lead in 1 of 2 comparable metrics.

PEN is the less volatile stock with a 0.23 beta — it tends to amplify market swings less than NVCR's 2.15 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 89.2% from its 52-week high vs SYK's 70.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricPEN logoPENPenumbra, Inc.ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedSYK logoSYKStryker Corporati…MDT logoMDTMedtronic plc
Beta (5Y)Sensitivity to S&P 5000.23x1.00x2.15x0.52x0.42x
52-Week HighHighest price in past year$362.41$603.88$20.06$404.87$106.33
52-Week LowLowest price in past year$221.26$427.84$9.82$284.97$75.91
% of 52W HighCurrent price vs 52-week peak+88.9%+74.5%+89.2%+70.5%+71.6%
RSI (14)Momentum oscillator 0–10038.143.670.926.629.2
Avg Volume (50D)Average daily shares traded533K1.8M1.4M2.1M7.9M
Evenly matched — PEN and NVCR each lead in 1 of 2 comparable metrics.

Analyst Outlook

MDT leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: PEN as "Hold", ISRG as "Buy", NVCR as "Buy", SYK as "Buy", MDT as "Buy". Consensus price targets imply 87.3% upside for NVCR (target: $34) vs 14.8% for PEN (target: $370). For income investors, MDT offers the higher dividend yield at 3.65% vs SYK's 1.18%.

MetricPEN logoPENPenumbra, Inc.ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedSYK logoSYKStryker Corporati…MDT logoMDTMedtronic plc
Analyst RatingConsensus buy/hold/sellHoldBuyBuyBuyBuy
Price TargetConsensus 12-month target$369.83$622.60$33.50$389.62$109.50
# AnalystsCovering analysts2255155049
Dividend YieldAnnual dividend ÷ price+1.2%+3.7%
Dividend StreakConsecutive years of raises3436
Dividend / ShareAnnual DPS$3.36$2.78
Buyback YieldShare repurchases ÷ mkt cap0.0%+1.4%0.0%0.0%+3.3%
MDT leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MDT leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.

Best OverallIntuitive Surgical, Inc. (ISRG)Leads 3 of 6 categories
Loading custom metrics...

PEN vs ISRG vs NVCR vs SYK vs MDT: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is PEN or ISRG or NVCR or SYK or MDT a better buy right now?

For growth investors, Intuitive Surgical, Inc.

(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Medtronic plc (MDT) offers the better valuation at 21. 1x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Intuitive Surgical, Inc. (ISRG) a "Buy" — based on 55 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — PEN or ISRG or NVCR or SYK or MDT?

On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.

1x versus Penumbra, Inc. at 71. 3x. On forward P/E, Medtronic plc is actually cheaper at 13. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 28x versus Medtronic plc's 35. 17x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — PEN or ISRG or NVCR or SYK or MDT?

Over the past 5 years, Intuitive Surgical, Inc.

(ISRG) delivered a total return of +61. 7%, compared to -90. 2% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ISRG returned +549. 2% versus MDT's +24. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — PEN or ISRG or NVCR or SYK or MDT?

By beta (market sensitivity over 5 years), Penumbra, Inc.

(PEN) is the lower-risk stock at 0. 23β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 838% more volatile than PEN relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

05

Which is growing faster — PEN or ISRG or NVCR or SYK or MDT?

By revenue growth (latest reported year), Intuitive Surgical, Inc.

(ISRG) is pulling ahead at 20. 5% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: Penumbra, Inc. grew EPS 1156% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, PEN leads at 18. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — PEN or ISRG or NVCR or SYK or MDT?

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is PEN or ISRG or NVCR or SYK or MDT more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 28x versus Medtronic plc's 35. 17x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Medtronic plc (MDT) trades at 13. 8x forward P/E versus 65. 8x for Penumbra, Inc. — 52. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 87. 3% to $33. 50.

08

Which pays a better dividend — PEN or ISRG or NVCR or SYK or MDT?

In this comparison, MDT (3.

7% yield), SYK (1. 2% yield) pay a dividend. PEN, ISRG, NVCR do not pay a meaningful dividend and should not be held primarily for income.

09

Is PEN or ISRG or NVCR or SYK or MDT better for a retirement portfolio?

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 1. 2% yield, +179. 2% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +179. 2%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between PEN and ISRG and NVCR and SYK and MDT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PEN is a mid-cap high-growth stock; ISRG is a mid-cap high-growth stock; NVCR is a small-cap quality compounder stock; SYK is a mid-cap quality compounder stock; MDT is a mid-cap income-oriented stock. SYK, MDT pay a dividend while PEN, ISRG, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

PEN

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 7%
Run This Screen
Stocks Like

ISRG

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Net Margin > 16%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

SYK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Stocks Like

MDT

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform PEN and ISRG and NVCR and SYK and MDT on the metrics below

Revenue Growth>
%
(PEN: 15.6% · ISRG: 23.0%)
Net Margin>
%
(PEN: 11.8% · ISRG: 28.2%)
P/E Ratio<
x
(PEN: 71.3x · ISRG: 57.2x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.